Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
So when people talk about GHK-Cu before and after results, theyre really talking about a restoration peptide, not a quick-fix cream
Womens Health Mens Health Obstetric shared care Antenatal and Postnatal Chronic disease management Mental Health Childhood and workplace immunizations On-site Clinpath Lab Allied healthcare services Open for Appointments HOW TO PAY South Road Day/Night Surgery Additional fees may apply for surgical procedures
MOTS-c and GHK-Cu follow their own schedules based on mechanism
Drug Testing and Analysis, 7(1), 31-38
